The global postoperative pain therapeutics market size reached US$ 13.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.86% during 2024-2032. The increasing number of orthopedic surgeries, improving healthcare infrastructure, and extensive research and development (R&D) activities represent some of the key factors driving the market.
|Market Size in 2023||US$ 13.7 Billion|
|Market Forecast in 2032||US$ 20.9 Billion|
|Market Growth Rate 2024-2032||4.86%|
Postoperative pain therapeutics refers to the various methods and medications used to reduce or eliminate pain and discomfort with minimal side effects. They include pain relievers, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, tricyclic antidepressants, and antiepileptic drugs. These medications provide relief from the distressing feeling caused due to postsurgical pain. Postoperative pain therapeutics are widely used to promote relaxation, reduce surgical stress, and improve overall patient outcomes. They are commonly administered to patients through oral, intravenous, and intramuscular routes. Postoperative pain therapeutics help patients feel comfortable, recover more quickly, and avoid adverse effects, such as prolonged pain and hospitalization, or risk of addiction to pain medications. They also assist in expediting the recovery process and reducing the chances of complications, such as pneumonia and blood clots.
The growing number of surgical procedures due to the rising prevalence of chronic diseases across the globe is one of the key factors driving the market growth. Postoperative pain therapeutics are widely used in phantom pain condition that occurs after thoracotomy, breast surgery, limb amputation, cesarean section, or inguinal hernia repair. In line with this, the widespread product adoption to manage heavy pain and soreness due to the increasing cases of road accidents and relative trauma injuries is favoring the market growth. Apart from this, key players are focusing on the development of postoperative pain therapeutics that are safer, more effective, economically viable, and easier to administer, which in turn is providing an impetus to the market growth. Moreover, the increasing adoption of the oral route of administration owing to its high preference for non-invasiveness, ease of use, and self-administration characteristics is acting as another growth-inducing factor. Additionally, the rising demand for NSAIDs to relieve pain, reduce inflammation, and bring down high body temperatures is propelling the market growth. Furthermore, the growing focus on improving patient experience and satisfaction and increasing awareness of adequate pain management is positively influencing the market growth. Other factors, including the increasing number of orthopedic surgeries, improving healthcare infrastructure, extensive research and development (R&D) activities, rising development and commercialization of non-narcotic drugs, and supportive government policies for novel drug discovery, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global postoperative pain therapeutics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug class, route of administration, and distribution channel.
Drug Class Insights:
The report has provided a detailed breakup and analysis of the postoperative pain therapeutics market based on the drug class. This includes opioids, NSAIDs, local anesthetics, tricyclic antidepressants, antiepileptic drugs, and others. According to the report, opioids represented the largest segment.
Route of Administration Insights:
A detailed breakup and analysis of the postoperative pain therapeutics market based on the route of administration has also been provided in the report. This includes oral, intravenous, intramuscular, and others. According to the report, oral accounted for the largest market share.
Distribution Channel Insights:
The report has provided a detailed breakup and analysis of the postoperative pain therapeutics market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for postoperative pain therapeutics. Some of the factors driving the North America postoperative pain therapeutics market included the growing number of surgical procedures, extensive research and development (R&D) activities, and significant technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global postoperative pain therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Heron Therapeutics, Mallinckrodt Pharmaceuticals, Pacira BioSciences, Inc., Pfizer, Inc., Trevena, Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis||2023|
|Scope of the Report||Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
|Drug Classes Covered||Opioids, NSAIDs, Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, Others|
|Route of Administrations Covered||Oral, Intravenous, Intramuscular, Others|
|Distribution Channels Covered||Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others|
|Regions Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Heron Therapeutics, Mallinckrodt Pharmaceuticals, Pacira BioSciences, Inc., Pfizer, Inc., Trevena, Inc., etc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
134 N 4th St. Brooklyn, NY 11249, USA
Level II & III, B-70, Sector 2, Noida, Uttar Pradesh 201301, India
30 Churchill Place London E14 5EU, UK
134 N 4th St. Brooklyn, NY 11249, USA
Level III, B-7 , Sector 2, Noida, Uttar Pradesh 201301, India
30 Churchill Place London E14 5EU, UK